Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Magenta Therapeutics Inc (MGTA)
NASDAQ:MGTA
Holding MGTA?
Track your performance easily
MGTA Stock Chart & Stats
Day’s Range$0.68 - $0.76
52-Week Range― - ―
Previous Close$0.76
Volume376.06K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Sep 18, 2023EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Magenta Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MGTA FAQ
What was Magenta Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Magenta Therapeutics Inc’s market cap?
Currently, no data Available
When is Magenta Therapeutics Inc’s upcoming earnings report date?
Magenta Therapeutics Inc’s upcoming earnings report date is Sep 18, 2023 which is 436 days ago.
How were Magenta Therapeutics Inc’s earnings last quarter?
Magenta Therapeutics Inc released its earnings results on May 11, 2023. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$0.07.
Is Magenta Therapeutics Inc overvalued?
According to Wall Street analysts Magenta Therapeutics Inc’s price is currently Overvalued.
Does Magenta Therapeutics Inc pay dividends?
Magenta Therapeutics Inc does not currently pay dividends.
What is Magenta Therapeutics Inc’s EPS estimate?
Magenta Therapeutics Inc’s EPS estimate is -$0.8.
How many shares outstanding does Magenta Therapeutics Inc have?
Currently, no data Available
What happened to Magenta Therapeutics Inc’s price movement after its last earnings report?
Magenta Therapeutics Inc reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went down -4.306%.
Which hedge fund is a major shareholder of Magenta Therapeutics Inc?
Among the largest hedge funds holding Magenta Therapeutics Inc’s share is Western Standard Llc. It holds Magenta Therapeutics Inc’s shares valued at N/A.
---
Magenta Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MGTA Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $271.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.41%
12-Months-Change
Fundamentals
Return on Equity
-65.34%
Trailing 12-Months
Asset Growth
-55.10%
Trailing 12-Months
Company Description
Magenta Therapeutics Inc
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
---
MGTA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Bellicum Pharmaceuticals
―
RegenXBio
―
Adverum Biotechnologies
―
Mersana Therapeutics
―
---